(Q33723312)

28 July 2017

title

Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay (English)

1 reference

28 July 2017

Allan Hildesheim

0 references

Sholom Wacholder

Sholom Wacholder

0 references

Michael Pawlita

Michael Pawlita

0 references

Ana Cecilia Rodríguez

Ana Cecilia Rodriguez

0 references

Mahboobeh Safaeian

Mahboobeh Safaeian

0 references

Tim Waterboer

Tim Waterboer

1 reference

28 July 2017

Hilary A Robbins

1 reference

28 July 2017

Douglas R Lowy

1 reference

28 July 2017

Mark Esser

1 reference

28 July 2017

Rolando Herrero

1 reference

28 July 2017

Ligia A Pinto

1 reference

28 July 2017

Carolina Porras

1 reference

28 July 2017

Troy J Kemp

1 reference

28 July 2017

Paula Gonzalez

1 reference

28 July 2017

John T Schiller

1 reference

28 July 2017

Katie Matys

1 reference

28 July 2017

Sylviane Poncelet

1 reference

28 July 2017

publication date

1 January 2014

1 reference

Human Vaccines & Immunotherapeutics

28 July 2017

published in

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

2965-2974

1 reference

Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Comparison of antibody responses to human papillomavirus vaccination as measured by three assays

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Human papillomavirus types 6 and 11 seropositivity: risk factors and association with ano-genital warts among homosexual men.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Reducing HPV-associated cancer globally.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Multiplexed serologic assay for nine anogenital human papillomavirus types

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Seroprevalence of 34 human papillomavirus types in the German general population

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Suppression of non-specific binding in serological Luminex assays

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5443057

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

21 June 2018

1 reference

https://api.crossref.org/works/10.4161%2F21645515.2014.972811

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2F21645515.2014.972811

Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2F21645515.2014.972811

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2F21645515.2014.972811

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2F21645515.2014.972811

Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2F21645515.2014.972811

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2F21645515.2014.972811

Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2F21645515.2014.972811

Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix®): A Guide to Its Two-Dose Schedule in Girls Aged 9–14 Years in the EU

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25483632

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/21645515.2014.972811

1 reference

28 July 2017

1 reference

28 July 2017

1 reference